Deprecated: mysql_connect(): The mysql extension is deprecated and will be removed in the future: use mysqli or PDO instead in /home/content/93/7713193/html/chandraprabhu/includes/dbconfig.php on line 20
imatinib manufacturer Chandraprabhu Pharma

imatinib manufacturer


Deprecated: mysql_connect(): The mysql extension is deprecated and will be removed in the future: use mysqli or PDO instead in /home/content/93/7713193/html/chandraprabhu/includes/dbconfig.php on line 20
Product Name :
IMATINIB
Chemical Formula :
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
CAS No :
152459-95-5
Molecular Formula :
C29H31N7O
Molecular Weight :
493.603
imatinib
Description :
Imatinib (originally STI571) is a drug used to treat certain cancers. Imatinib is the first of a new class of drugs that act by specifically inhibiting a certain enzyme (a receptor tyrosine kinase) that is characteristic of a particular cancer cell, rather than non-specifically inhibiting and killing all rapidly dividing cells. Imatinib was a model for other targeted therapies that inhibited this class of enzymes. It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases. In CML, the tyrosine kinase enzyme ABL in white blood cells is constantly (constitutively) expressed. This causes the excessive proliferation and high white blood cell count which is characteristic of CML. Imatinib binds to the site of tyrosine kinase activity, and prevents its activity, causing tumor cell death. Imatinib is used in chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. As this is now a constitutively active tyrosine kinase, imatinib is used to decrease bcr-abl activity. The active sites of tyrosine kinases each have a binding site for ATP. The enzymatic activity catalyzed by a tyrosine kinase is the transfer of the terminal phosphate from ATP to tyrosine residues on its substrates, a process known as protein tyrosine phosphorylation. Imatinib works by binding close to the ATP binding site of bcr-abl, locking it in a closed or self-inhibited conformation, and therefore inhibiting the enzyme activity of the protein semi-competitively.

Submit Enquiry